[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639226":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":33,"locations":38,"responsibleParty":55,"collaborators":59,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":33,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":87,"whyStopped":33,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Tirzepatide + Lifestyle Intervention","EXPERIMENTAL","Participants receive subcutaneous tirzepatide once weekly for 12 months in addition to guideline-directed lifestyle intervention.\n\nDose escalation: 2.5 mg\u002Fweek for weeks 1-4; 5 mg\u002Fweek for weeks 5-8; 7.5 mg\u002Fweek for weeks 9-12; 10 mg\u002Fweek from week 13 onward (target); may be escalated to 15 mg\u002Fweek if tolerated. All participants additionally receive a structured lifestyle intervention identical to the control arm.",[13,14],"Drug: Tirzepatide","Behavioral: Structured Lifestyle Intervention",{"label":16,"type":17,"description":18,"interventionNames":19},"Lifestyle Intervention","ACTIVE_COMPARATOR","Participants receive guideline-directed standard care for AF, anticoagulation, and HFpEF, without any GLP-1 receptor agonist or GIP\u002FGLP-1 dual agonist.\n\nThe same structured lifestyle intervention as the experimental arm is delivered, including monthly dietitian-led counseling, exercise prescription, and sleep apnea screening, to ensure equal follow-up intensity.",[14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tirzepatide","Dual GIP and GLP-1 receptor agonist administered as a weekly subcutaneous injection.\n\nTitrated from 2.5 mg\u002Fweek to a target of 10 mg\u002Fweek (maximum 15 mg\u002Fweek) over 12 weeks, then maintained at the maximum tolerated dose for the remainder of the 12-month treatment period.",[9],[27],"Mounjaro",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"BEHAVIORAL","Structured Lifestyle Intervention","Guideline-directed AF management (rate\u002Frhythm control, anticoagulation by CHA2DS2-VASc).\n\nGuideline-directed HFpEF therapy (MRA, SGLT2 inhibitor as clinically indicated).\n\nStructured lifestyle intervention: monthly dietitian-led counseling targeting a 500 kcal\u002Fday caloric deficit; exercise prescription of ≥150 min\u002Fweek moderate aerobic; smoking cessation and alcohol moderation counseling.",[16,9],null,[35],{"name":36,"affiliation":5,"role":37},"Yunlong Wang, PHD","PRINCIPAL_INVESTIGATOR",[39],{"facility":5,"status":33,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Beijing","Beijing Municipality","100029","China","CN",{"type":46,"coordinates":47},"Point",[48,49],116.39723,39.9075,{"lat":49,"lon":48},[52],{"name":33,"role":53,"phone":33,"phoneExt":33,"email":54},"CONTACT","wang_lili1002@163.com",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"SPONSOR_INVESTIGATOR","Yunlong Wang","Chief Physician; Professor;",[60],{"name":61,"class":6},"Shanghai Zhongshan Hospital","100639226","phase-4-tirzepatide-on-atrial-fibrillation-recurrence-after-catheter-ablation-in-patients-with-obesity-and-hfpef-100639226",false,"NCT07630454","Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF","Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Obese and HFpEF: A Randomized Controlled Trial","TEAR-AF-HFpEF","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Symptomatic atrial fibrillation (paroxysmal or persistent of ≤ 5 years duration), undergoing first-time catheter ablation\n* Body weight criteria (aligned with NMPA-approved tirzepatide indication)，meeting at least one of the following:\n\n  * BMI ≥28.0 kg\u002Fm² (obesity threshold per Chinese criteria), OR\n  * BMI ≥24.0 kg\u002Fm² and \\\u003C28.0 kg\u002Fm² (overweight per Chinese criteria) with at least one weight-related comorbidity: hypertension, dyslipidemia, type 2 diabetes mellitus (T2DM), obstructive sleep apnea syndrome (OSAS), or atherosclerotic cardiovascular disease (ASCVD)\n* HFpEF defined by intraprocedural mean left atrial pressure ≥ 15 mmHg at rest\n* Left ventricular ejection fraction ≥ 50% on echocardiography within 30 days prior to enrollment\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Prior use of any GLP-1 receptor agonist or GIP\u002FGLP-1 dual receptor agonist\n* Type 1 diabetes mellitus; or type 2 diabetes with HbA1c \\> 10%\n* Personal history of pancreatitis; personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)\n* Severe gastrointestinal disease, including gastroparesis or active inflammatory bowel disease\n* Prior bariatric surgery\n* Moderate or severe valvular heart disease, hypertrophic cardiomyopathy, cardiac amyloidosis, constrictive pericarditis, or restrictive cardiomyopathy\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Active malignancy, excluding basal cell carcinoma\n* Acute coronary syndrome, stroke, percutaneous coronary intervention, or cardiac surgery within 30 days prior to enrollment\n* Pregnancy, lactation, or planned pregnancy within 6 months\n* Life expectancy \\\u003C 12 months\n* Concurrent participation in another interventional clinical trial\n* Any condition that, in the investigator's judgment, would interfere with participation","ALL","18 Years","80 Years",{"count":74,"type":75},602,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","This multicenter, randomized, open-label, blinded-endpoint trial evaluates whether weekly subcutaneous tirzepatide for 12 months reduces atrial fibrillation (AF) recurrence after catheter ablation in adults with obesity and heart failure with preserved ejection fraction (HFpEF). HFpEF is diagnosed by direct intraprocedural measurement of mean left atrial pressure (mLAP ≥ 15 mmHg at rest) during the ablation procedure, providing a hemodynamically anchored, homogeneous study population free from the diagnostic ambiguities of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and E\u002Fe' in AF patients. Approximately 602 participants will be randomized 1:1 to tirzepatide (titrated to a target of 10 mg\u002Fweek, maximum 15 mg\u002Fweek) plus standard care, or standard care alone. Both groups receive an identical structured lifestyle intervention. The primary endpoint is the first documented AF\u002Fatrial flutter\u002Fatrial tachycardia episode lasting ≥ 30 seconds, occurring between day 91 and day 365 after ablation, adjudicated by an independent blinded clinical endpoint committee.",[81,82,23],"Atrial Fibrillation","Heart Failure With Preserved Ejection Fraction (HFpEF)",[81,23,84,85,86],"GIP\u002FGLP-1 receptor agonist","Obesity","HFpEF","NOT_YET_RECRUITING","2026-06-03",{"date":90,"type":91},"2026-06-05","ACTUAL",{"date":93,"type":75},"2026-08-01",{"date":95,"type":75},"2029-12-01",{"name":57,"class":6},1]